Day: July 9, 2021

Global Extended Reality Market size expected to grow from 33 billion USD in 2021 to over 125 billion USD in 2026, at CAGR of 30%

US online sports betting market size expected to grow at 50% CAGR to reach 15 billion by 2025

Online gambling market size expected to grow at 11.5% CAGR to reach 127 billion USD by 2027

SAN JUAN, Puerto Rico, July 09, 2021 (GLOBE NEWSWIRE) — via InvestorWire — XR Casino, Inc (“XR Casino” or “The Company”), the first-ever cross-technology, multiplayer, blockchain technology-based online gambling platform for Extended Reality (XR) technologies such as Augmented Reality (AR), Mixed Reality (MR) and Virtual Reality (VR), today announces its MVP release date.

The Company is developing the first-ever extended reality platform that will allow users of different devices to play XR casino games with each other. The initial games include blackjack, roulette and slots and will be featured in its MVP version launching on August 21, 2021. Sports betting, baccarat, bingo, craps, poker and keno are in the development pipeline.

The list of supported devices includes Microsoft’s Hololens 1 and 2, Magic Leap’s Magic Leap 1, HTC Vive, Oculus Quest 2, Samsung’s Gear VR and AR-enabled smartphones as well as devices such as the Apple iPhone, iPad and over 39 Android smartphones and devices.

Game features include:

• Multiplayer Games
• Private Game Rooms
• Public Game Rooms
• Text and Voice Chats

“XR technologies are changing the way we interact with each other and eliminating the need for expensive equipment,” said XR Casino CEO Dan Martinez. “Tech giants such as Apple, Google, Facebook and Microsoft have invested heavily into AR, VR and MR to speed up mass adoption through both hardware and software solutions. XR Casino has first mover’s advantage in providing XR SaaS solutions to online, traditional casinos and sports betting companies. Our solutions create value for the gambling industry and offer competitive differentiation to attract new Generation X, Y and Z players worldwide.”

About XR Casino, Inc.

XR Casino, Inc. is the first-ever cross-technology, multiplayer, blockchain technology-based online gambling platform for Extended Reality (XR) technologies such as Augmented Reality (AR), Mixed Reality (MR) and Virtual Reality (VR). For more information visit www.xr.casino.

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as may be disclosed in the Company’s filings. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors, including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release, and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release. Such forward-looking statements are risks that are detailed in the Company’s website and filings.

Contact:
info@xr.casino
investors@xr.casino

Wire Service
InvestorWire
Los Angeles, California
www.InvestorWire.com
212.418.1217
Editor@InvestorWire.com

Photos available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/ed5cfbf3-755a-4c5f-a832-9d14cafd7e7f
https://www.globenewswire.com/NewsRoom/AttachmentNg/cfda210a-f73a-4a23-909d-d1a5967ecda4
https://www.globenewswire.com/NewsRoom/AttachmentNg/a3c72329-0755-4e6e-a3ef-fa58045a6e2e

QuantuMDx launches Q-POC™ – rapid PCR point of care diagnostic system

• Roll out at ECCMID 2021 with Q-POC™ SARS-CoV-2 assay
• 96.9% sensitivity, 98.3% specificity
• Sample to result – approximately 30 minutes
• CE-IVD marked – available to order now

NEWCASTLE UPON TYNE, UK, 09 July 2021. QuantuMDx Group Limited (‘QuantuMDx’ or the ‘Company’), a UK-based developer of transformational point-of-care diagnostics, today announces the launch of Q-POC™ – a rapid, PCR point of care diagnostic system.

Launching at ECCMID 2021, QuantuMDx’s Q-POC™ system and its first test, a SARS-CoV-2 detection assay, are now CE-IVD marked under the In Vitro Diagnostics Directive (98/79/EC), enabling use within Europe.

The Q-POC™ SARS-CoV-2 assay has been evaluated at St George’s, University of London, to assess clinical performance against tests in current use. The Development & Assessment of Rapid Technology (DART) Study shows 96.9% sensitivity (at CTs <35), 98.3% specificity and 0% cross reactivity with common commensal or potentially interfering organisms.

Q-POC™ is a portable PCR system which compresses an entire molecular diagnostic laboratory into a simple to use, accessible and affordable single device offering rapid, molecular diagnostic testing at the point of care, with results in approximately 30 minutes. Q-POC™ has been designed for front-line healthcare professionals and can be used within a wide range of settings, including emergency rooms, ICU, birthing centres, clinics, and pharmacies.

The Q-POC™ SARS-CoV-2 assay is contained within a sealed, single use test cassette designed for safety, ease of use and to eliminate contamination risk. On-board reagents are also lyophilised for room temperature storage, convenient shipping and a longer shelf life.

QuantuMDx’s Q-POC™ SARS-CoV-2 Assay has been designed with the most up-to-data sequence information to ensure 100% coverage of all known SARS-CoV-2 sequences.

Jonathan O’Halloran, Chief Executive, QuantuMDx, said: “Q-POC™ represents a new class of molecular diagnostic device: it’s fast, battery operated, can multiplex and is so simple to operate that anyone can be trained to use it. It’s a true point of care diagnostic system.

“Our Q-POC™ system is future-proof, and packs a great deal of complexity and power behind its modern lines and simple operation. Our SARS-CoV-2 test is just the first in a portfolio designed to meet real clinical needs. Over the next few years, we’ll be driving menu expansion, comprising large syndromic panels and antimicrobial resistance mutation panels, ensuring we remain at the forefront of molecular, point of care diagnostics globally.”

Sanjeev Krishna, Professor of Molecular Parasitology and Medicine at St George’s, University of London, said: “We are simply delighted to see the successful outcome of years of efforts to compress a diagnostics laboratory into a simple, portable and flexible device. The Q-POC™ platform was invented to address urgent diagnostic needs, particularly for pinch points for COVID-19 management in the NHS, and the community. In addition, how great is it to see the Northern Powerhouse delivering for us, with great potential to expand quickly and tackle other looming challenges like winter flu and antimicrobial resistance.”

Jonathan O’Halloran added: “Working with our British manufacturing partner, Cogent Technology and Singapore-based, Univac, we have scaled manufacturing to ensure security of supply for our customers and we are excited to be open for business.”

QuantuMDx was awarded £16m UK government funding in March 2020 to develop the company’s portable diagnostic testing system, Q-POC™, and disposable cassettes to allow for rapid, point-of-care testing for the SARS-CoV-2 virus in high and low-resource settings. The funding also included £3.2m towards production of QuantuMDx’ lab-based coronavirus test which is now commercially available.

For more information about QuantuMDx and Q-POC™, its rapid PCR point of care system, go to: www.quantumdx.com.

Notes to editor:

1)   Q-POC™ brochure and video

2)   Professor Sanjeev Krishna is a shareholder and advisor to QuantuMDx

About QuantuMDx:

QuantuMDx Group is an ambitious company with a global vision of empowering the world to control and eradicate disease by making transformative, quality point-of-care diagnostic technologies universally accessible. QuantuMDx has operations and strategic partnerships in the United States, Asia, Australasia, Europe and Africa – keeping it at the forefront of molecular diagnostics. For more information go to: www.quantumdx.com

For media enquiries:

Debra Daglish, Marketing Communications Manager, QuantuMDx Group, 0870 803 1234

Chris Gardner, Matthew Neal and Lindsey Neville, Consilium Strategic Communications, 0203 709 5700 / quantumdx@consilium-comms.com

For investor enquiries:

Financial Adviser: WG Partners LLP; David Wilson (020 3705 9315), Nigel Barnes (020 3705 9318), Claes Spång (020 3705 9317)

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Announces Closing of Nasdaq Initial Public Offering and Underwriters’ Full Exercise of Option to Purchase Additional Shares

Mont-Saint-Guibert, Belgium – July 8, 2021, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the closing on July 7, 2021 of its initial public offering in the United States (the “Offering”) of 2,835,000 ordinary shares at a price to the public of US$30 per share for total gross proceeds of US$85.1 million before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Nyxoah announced today that the underwriters of the Offering have exercised their option to purchase additional shares in full. The option to purchase additional shares granted to the underwriters was for the purchase of up to an additional 425,250 new ordinary shares, at the public offering price of US$30 per share, before underwriting discounts and commissions. This exercise will bring the total gross proceeds of the Offering to US$97.8 million before deducting underwriting discounts and commissions and estimated offering expenses.   The closing of the exercise of the option to purchase additional shares is expected to occur on July 9, 2021, subject to the satisfaction of customary closing conditions.

Piper Sandler, Stifel and Cantor acted as joint book-running managers for the offering. Degroof Petercam acted as a co-manager.

A registration statement relating to the ordinary shares was filed with the Securities and Exchange Commission (“SEC”) and declared effective on June 30, 2021. This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification or publication of an offering prospectus under the securities laws of any such state or jurisdiction.

The offering of ordinary shares was made only by means of a prospectus. A copy of the final prospectus can be obtained from Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by e-mail at prospectus@psc.com, or by phone at (800) 747-3924; Stifel, Nicolaus & Company, Incorporated at Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 4th Floor, New York, New York 10022; email: prospectus@cantor.com.

Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the closing of the shares to be sold pursuant to the exercise of the option to purchase additional ordinary shares. Forward-looking statements are based on Nyxoah’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and could cause actual results to differ. Forward-looking statements contained in this announcement are made as of this date, and Nyxoah undertakes no duty to update such information except as required under applicable law.

IMPORTANT INFORMATION
No public offering will be made and no one has taken any action that would, or is intended to, permit a public offering in any country or jurisdiction, other than the United States, where any such action is required, including in Belgium. Belgian investors, other than qualified investors within the meaning of the Belgian Act of 11 July 2018 on the public offering of securities and the admission of securities to be traded on a regulated market, will not be eligible to participate in the offering (whether in Belgium or elsewhere). The transaction to which this press release relates will only be available to, and will be engaged in only with, in member states of the European Economic Area, persons falling within the meaning of Article 2(e) of Regulation (EU) 2017/1129 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market (the “Prospectus Regulation”), and in the United Kingdom, investment professionals falling within article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), persons falling within article 49 (2), (a) to (d) of the Order and other persons to whom it may lawfully be communicated. A listing prospectus will be prepared by Nyxoah in accordance with Article 3 of the Prospectus Regulation for the purpose of having the new ordinary shares, issued pursuant to the Offering and the exercise by the underwriters of their option to purchase additional ordinary shares, admitted to trading on Euronext Brussels.

Contacts:
Nyxoah
Fabian Suarez, Chief Financial Officer
corporate@nyxoah.com
+32 (0)10 22 24 55

Gilmartin Group
Vivian Cervantes
IR@nyxoah.com

Attachment

• Nyxoah – 2021 Offering – Exercise greenshoe – ENG (final)